Safety, Tolerance, Pharmacokinetics and Activity of HE3286 in Patients With Rheumatoid Arthritis

Harbor Therapeutics

Status and phase: Completed; Phase 2; Phase 1

Conditions: Rheumatoid Arthritis

Treatments: Drug: HE3286

Study type: Interventional

Funder types: Industry

Identifiers

NCT00712114

HE3286-0201

Details and patient eligibility

About

The purpose of this pilot, exploratory study is to evaluate the safety, tolerance, pharmacokinetics and potential anti-inflammatory activity of an investigational agent, HE3286, when administered orally for 29 days to patients with rheumatoid arthritis that are taking a stable dose of methotrexate.

Full description

This is a Phase I/II, open label, dose ranging study of the safety, tolerance, and anti-inflammatory activity of HE3286 in patients with rheumatoid arthritis. Patients will receive study treatment (one of three open label doses) in addition to their current stable dose of methotrexate. Safety (via monitoring of vital signs, physical examination changes, ECG results, laboratory results, and adverse events), pharmacokinetics profiles (of HE3286 and methotrexate) and anti-inflammatory activity will be assessed over a treatment period of 29 days.

Enrollment: 14 patients

Sex: All

Ages: 18 to 75 years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Main Inclusion Criteria:

• Male or female patient 18-75 years of age
• Patient with stable or active disease on a stable dose of methotrexate for at least 30 days prior to Day 1
• Patient has normal thyroid stimulating hormone (TSH) levels with or without thyroid replacement therapy
• Patient is willing to abstain from consuming grapefruit containing products from 24 hours prior to dosing until the end of the study as it may affect the pharmacokinetic measurements
• Patient has not experienced renal or liver disease by history and/or based on laboratory results
• Patient has not experienced acute cardiac disease within 6 months prior to Screening
• Patient must provide voluntary, written, informed consent prior to screening evaluations and be able to follow verbal and written instructions.

Main Exclusion Criteria:

• Functional status class IV according to The American College of Rheumatology (ACR) criteria

• Patient who has a history of clinically significant cardiovascular disease (including coronary artery disease), clinically significant hepatic, respiratory or renal abnormalities, or clinically significant endocrine disorders (including diabetes)

• Patient with active Tuberculosis (TB) or evidence of latent TB without previous adequate therapy

• Systemic autoimmune disorder (including, but not limited to, systemic lupus erythematosus, inflammatory bowel disease, scleroderma, inflammatory myopathy, mixed connective tissue disease or any overlap syndrome)

• Inflammatory joint disease other than RA

• Patient who has received any of the following immunosuppressive drugs:

  • Etanercept within 1 month of Day 1;
  • Abatacept, adalimumab, infliximab, leflunomide, imuran, cyclosporin, anakinra, sulfasalazine, bextra, celebrex or gold within 2 months of Day 1 or for biological agents 6 half lives, whichever is greater;
  • Rituximab within 1 year of Day 1

• Patient that is bed or wheelchair bound

• Patients taking prednisone within 2 weeks prior to Screening

• Patient requiring or receiving any of the following within thirty (30) days prior to the screening visit: interleukins, steroids (i.e., anabolic steroids, glucocorticoids), hormone replacement therapy (except stable low-dose HRT for at least 6-months prior to screening), birth control pills, anti-cancer chemotherapeutic agents (except methotrexate), metabolic inhibitors (except methotrexate), concomitant medications that prolong the QT/QTc interval

• Patient who has any clinically significant abnormalities in laboratory results at Screening

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Single Group Assignment

Masking: None (Open label)

---

14 participants in 3 patient groups

Cohort 1

Experimental group

Description:

10 mg HE3286 (1 x 5 mg HE3286, BID)

Treatment:

Drug: HE3286

Drug: HE3286

Drug: HE3286

Cohort 2

Experimental group

Description:

20 mg HE3286 (2 x 5 mg HE3286 BID)

Treatment:

Drug: HE3286

Drug: HE3286

Drug: HE3286

Cohort 3

Experimental group

Description:

40 mg HE3286 (4 x 5 mg HE3286 BID)

Treatment:

Drug: HE3286

Drug: HE3286

Drug: HE3286